Design Therapeutics, Inc. (DSGN)
NASDAQ • Healthcare
Last close at September 9, 2026 at 20:00 UTC
Metrics Over Time
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 4
in 55 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
About Design Therapeutics, Inc.
Design Therapeutics, Inc. is a NASDAQ-listed biotechnology company developing medicines for genetic disorders rooted in nucleotide repeat expansions. In qualitative terms, it is an early-stage biotech business. The company centers its work on GeneTAC, a product candidate platform aimed at monogenic conditions caused by these repeat-driven defects.
Today's Snapshot
DSGN is trading 1% lower at 14.88, while its sector was flat. Design Therapeutics presented its biomarker work at a Cantor investor conference.
Trading Volume
Below 10d avg (588.5K)
261.1K
vs S&P 500 Today
Moderate Underperformance
-0.41%
Updated: September 10, 2026 at 16:51 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$11.59 - $15.12Buy
- RSI (14)52.67Neutral
- Stochastic %K (14, 3, 3)41.44Neutral
- MACD Level (12, 26)0.32Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.